| Loperamide: a pharmacological review. DE Baker Reviews in gastroenterological disorders 7, S11-8, 2007 | 204 | 2007 |
| Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus JL Iltz, DE Baker, SM Setter, RK Campbell Clinical therapeutics 28 (5), 652-665, 2006 | 137 | 2006 |
| Miglitol: assessment of its role in the treatment of patients with diabetes mellitus LK Campbell, DE Baker, RK Campbell Annals of Pharmacotherapy 34 (11), 1291-1301, 2000 | 134 | 2000 |
| Phosphodiesterase 5 inhibitors for erectile dysfunction SM Setter, JL Iltz, JE Fincham, RK Campbell, DE Baker Annals of Pharmacotherapy 39 (7-8), 1286-1295, 2005 | 107 | 2005 |
| New drugs in development for the treatment of diabetes. TL Levien, DE Baker Diabetes Spectrum 22 (2), 92-107, 2009 | 96 | 2009 |
| Insulin glargine: a new basal insulin TL Levien, DE Baker, JR White Jr, RK Campbell Annals of Pharmacotherapy 36 (6), 1019-1027, 2002 | 88 | 2002 |
| Rationale for using serotonergic agents to treat irritable bowel syndrome DE Baker American Journal of Health-System Pharmacy 62 (7), 700-711, 2005 | 81 | 2005 |
| Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B. DE Baker Reviews in Gastroenterological Disorders 5 (2), 89-100, 2005 | 80 | 2005 |
| Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. DE Baker Reviews in Gastroenterological Disorders 3 (2), 93-109, 2003 | 75 | 2003 |
| Pegylated interferons. DE Baker Reviews in Gastroenterological Disorders 1 (2), 87-99, 2001 | 70 | 2001 |
| Insulin glargine RK Campbell, JR White, T Levien, D Baker Clinical therapeutics 23 (12), 1938-1957, 2001 | 69 | 2001 |
| Rifaximin: a nonabsorbed oral antibiotic. DE Baker Reviews in Gastroenterological Disorders 5 (1), 19-30, 2005 | 58 | 2005 |
| Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the colon or rectum. DE Baker Reviews in Gastroenterological Disorders 3 (1), 31-38, 2003 | 52 | 2003 |
| Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. DE Baker Reviews in Gastroenterological Disorders 4 (4), 196-210, 2004 | 47 | 2004 |
| Nateglinide therapy for type 2 diabetes mellitus TL Levien, DE Baker, RK Campbell, JR White Jr Annals of Pharmacotherapy 35 (11), 1426-1434, 2001 | 44 | 2001 |
| Tofacitinib DJ Cada, K Demaris, TL Levien, DE Baker Hospital pharmacy 48 (5), 413-424, 2013 | 43 | 2013 |
| Vitamin and mineral supplementation in patients with diabetes mellitus DE Baker, RK Campbell The Diabetes Educator 18 (5), 420-427, 1992 | 41 | 1992 |
| Natalizumab: overview of its pharmacology and safety. DE Baker Reviews in Gastroenterological Disorders 7 (1), 38-46, 2007 | 37 | 2007 |
| Rabbit intrafusal muscle fibres. D Baker, MJ Stacey The Journal of Physiology 210 (2), 70P-72P, 1970 | 37 | 1970 |
| Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. DE Baker Reviews in Gastroenterological Disorders 2 (1), 20-33, 2002 | 35 | 2002 |
